Links between FGF21 and carbohydrate consumption have recently been described, with both genomic associations and elevated FGF21 levels in healthy subjects following sugar ingestion. In this issue, von Holstein- Rathlou et al. (2016) and Talukdar et al. (2016) demonstrate a mechanistic role for FGF21 in the regulation of macronutrient preference.
Fibroblast growth factor 21 (FGF21) is a pleiotropic endocrine factor, induced during states of metabolic stress such as prolonged fasting and consumption of high-fat/high-sucrose diets. To mediate its effects, FGF21 requires an FGF receptor and the obligate co-factor klotho-b (KLB) in its target organs, which include adipose tissue, liver, and discrete regions of the CNS. Recently, it was reported that consumption of refined carbohydrates, such as fructose, lead to a robust and rapid elevation of FGF21 levels in healthy volunteers (Dushay et al., 2015) . Evidence in vitro and in rodents suggests that this induction is likely mediated by the transcription factor Carbohydrate Responsive-Element Binding Protein (ChREBP), which is potently activated by fructose (Sá nchez et al., 2009) . Genomic data suggest that FGF21 is not only regulated by carbohydrates, but in turn may itself regulate carbohydrate intake. Specifically, SNPs in and around the FGF21 gene have been reported to be associated with enhanced preference for carbohydrates, raising the question of whether altered FGF21 levels can impact macronutrient choice (Chu et al., 2013; Tanaka et al., 2013) .
In this issue of Cell Metabolism, studies by two independent groups (von HolsteinRathlou et al., 2016; Talukdar et al., 2016) significantly expand on this line of evidence, demonstrating for the first time that genetic or pharmacological alterations of FGF21 levels affect carbohydrate preference in multiple species and provide a mechanistic basis for the link between FGF21 and carbohydrate preference. First, von Holstein-Rathlou et al. (2016) show that the induction of FGF21 by sweets is indeed mediated by ChREBP, as animals lacking the transcription factor did not induce FGF21 in response to a bolus of various sugars. Next, in FGF21 null mice, they demonstrated that preference for carbohydraterich foods is significantly enhanced. Conversely, mice overexpressing FGF21 or animals treated with recombinant FGF21 exhibited significantly reduced consumption of both sugar and synthetic sweeteners, with no apparent effect on fat or protein intake. Importantly, von Holstein-Rathlou et al. (2016) showed that this change in preference is not mediated via an aversive response to sweet stimuli, nor is it due to direct effects of FGF21 on the epithelial cells responsible for taste perception. Through an elegant series of region-specific deletions of KLB in the CNS, von Holstein-Rathlou et al. (2016) were able to localize this sucrose preference effect to the paraventricular nucleus (PVN) of the hypothalamus, an area recently demonstrated as being FGF21 responsive (Douris et al., 2015) . These data suggest a negative feedback loop whereby FGF21, secreted in response to ChREBP activation, acts in an endocrine manner to alter food preference in the PVN (Figure 1) .
In a related study, Talukdar et al. (2016) also found that FGF21 administration was able to potently reduce the preference for sweet foods and that this effect requires KLB expression in the brain. Importantly, these authors extend the work to higher species, demonstrating that monkeys treated with the FGF21 analog PF-05231023 also show decreased carbohydrate preference. In mice, administration of PF-05231023 altered expression of dopamine-related genes in several nuclei linked to the dopaminergic reward system, including the ventral tegmental area (VTA) and the nucleus accumbens (NAc). KLB was found to be expressed, albeit at low levels, in these two nuclei, suggesting that FGF21 may control reward behavior through direct actions on dopaminergic neurons. Interestingly, FGF21 overexpressing mice showed decreased alcohol preference as well, suggesting that additional reward systems may be regulated by FGF21. While expression of KLB allows for direct action of FGF21 on the VTA and the NAc, it is important to consider that secondary effects downstream of FGF21 action in the PVN remain a possibility (Figure 1) .
These studies add to the growing body of data demonstrating diverse effects of FGF21 in the CNS. Since FGF21 is generally thought not to be widely expressed in the brain, it will be important to delineate the neuronal pathways activated by FGF21 and the mechanisms by which peripheral FGF21 reaches its CNS target neurons. The latter is of direct pharmacological relevance, as a number of approaches targeting the FGF21 pathway have employed time extension strategies, which dramatically decrease central availability, e.g., the Fc-conjugation approach employed in PF-05231023 (Tabrizi et al., 2010) . Studies directly examining the ability of FGF21 to cross the blood-brain barrier have been limited to a single publication to date (Hsuchou et al., 2007) , and no distribution studies of peripherally injected FGF21 in specific brain nuclei have been conducted. It will also be important to genetically confirm the source of FGF21 mediating this CNSmediated food preference effect as peripheral in nature, by utilizing mice with tissue-specific ablation of FGF21 in the liver or in discrete neuronal populations in regions such as the PVN and NAc.
Taken together, these studies present a novel feedforward loop in which consumption of sweet foods leads to an acute increase in FGF21 expression, which then acts via the PVN to suppress further consumption, with a concomitant reduction in DA levels in the reward center of the brain. However, the precise evolutionary reason as to why FGF21 would limit the consumption of energy dense foods or alter their rewarding properties remains unknown. Since FGF21 strongly activates lipid catabolism, especially in man (Gaich et al., 2013) , it is possible that decreased carbohydrate intake provides a way to limit lipid accumulation by decreasing de novo lipogenesis, which may help prevent adverse events associated with overactive lipid oxidation, for example, excessive ketosis or ROS production. A second question is whether the effects observed regarding macronutrient preference will translate into man. Obese individuals exhibit significantly elevated levels of FGF21 in plasma, potentially due to elevated consumption of dietary sugars such as fructose; however, it appears that this increase is not sufficient to blunt further consumption. This again raises the specter of FGF21 resistance, a phenomenon that has been shown to be linked to reduced expression of KLB in adipose tissue. However, the work of von Holstein-Rathlou et al. (2016) and Talukdar et al. (2016) suggests that when it comes to sweets and alcohol it may be central FGF21 resistance we should be worried about. In conclusion, both correlative and causal data linking FGF21 to the consumption of individual macronutrients and even to substances of abuse, such as alcohol, now exist. These data provide a novel and exciting research direction for the study of FGF21 in the regulation of macronutrient preference, the translational relevance of which urgently needs to be established.
Figure 1. The Role of FGF21 in Macronutrient Preference
In response to dietary intake of carbohydrates, activation of ChREBP in the liver leads to the enhanced production of FGF21, which is then released and acts in an endocrine manner in the paraventricular nucleus of the hypothalamus (PVN), serving to limit the consumption of carbohydrates, thus representing a potential negative feedback loop. FGF21 may also act to reduce levels of the neurotransmitter dopamine in the nucleus accumbens (NAc), restricting the reward derived from intake of sugars. Further study is required to determine the contribution of hepatic FGF21 acting in an endocrine manner versus locally produced FGF21 in the brain acting in an autocrine manner, especially in deeper regions such as the accumbens.
